Cellectis (CLLS) Reports Q3 Loss of $0.36/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Cellectis Reports Financial Results for 3rd Quarter and First Nine Months 2016
November 22, 2016 5:01 PM EST- UCART19 Phase 1 trial on-going
- Successful cGMP Manufacturing for UCART123
- Strong cash position of $295 million1 as of September 30, 2016
- Additional grant of patent with broad claims covering fundamental use of gene editing technologies
- Revenues and other income of $12 million2 in the 3rd quarter of 2016
- Adjusted loss attributable to shareholders3 of $0.6 million2 in the 3rd quarter of 2016
NEW YORK--(BUSINESS WIRE)-- Regulatory News:
Cellectis S.A. (Paris: ALCLS) (NASDAQ: CLLS) (Alternext: ALCLS - Nasdaq: CLLS), a biopharmaceutical company focused on... More
